Worldwide availability of medications for migraine and tension-type headache: A survey of the International Headache Society.

Autor:	Puledda F; Headache Group, Wolfson SPaRC, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK., de Boer I; Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands., Messina R; Neuroimaging Research Unit and Neurology Unit, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy., Garcia-Azorin D; Headache Unit, Department of Neurology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Portes Souza MN; Neurology Department, Universidade de São Paulo, São Paulo, Brazil., Al-Karagholi MA; Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Copenhagen, Denmark., de Dhaem OB; Hartford HealthCare, University of Connecticut, Westport, Connecticut, USA., Tassorelli C; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.; Headache Science & Neurorehabilitation Center, IRCCS C. Mondino Foundation, Pavia, Italy., May A; Dept. of Systems Neuroscience, University Clinic Hamburg Eppendorf, Hamburg, Germany.
Jazyk:	angličtina
Zdroj:	Cephalalgia : an international journal of headache [Cephalalgia] 2024 Nov; Vol. 44 (11), pp. 3331024241297688.
DOI:	10.1177/03331024241297688
Abstrakt:	Background: In this study, we aimed to evaluate the differing global access to acute and preventive medications for migraine and tension-type headache. Methods: A custom-built questionnaire created by members of the International Headache Society Juniors Group was sent to International Headache Society members worldwide, including a list of acute and preventive treatments for migraine and tension-type headache. This list was based on evidence-based medicine guidelines. For each treatment, participants were asked about availability, type of reimbursement and variability of access within their country. Results: Eighty-four members completed the questionnaire providing data for 84 countries. The majority were neurologists (88%) and worked at an academic/university hospital (62%). Of participants, 36% were located in high-income economy countries and 13% were located in low-income economies. Common preventive treatments such as propranolol and topiramate were available in most countries (respectively in 99% and 92% of responding countries). Sumatriptan was available in most countries (95%), whereas other triptan availability was lower. Novel migraine treatments such as rimegepant and erenumab were only available in 14% and 46% of the assessed countries, respectively. Conclusions: Availability of headache medications, ranging from simple analgesics to novel therapies migraine-specific drugs, varied greatly across the world. Actions are needed to improve effective drug availability in many countries to ensure an adequate management of people living with headache. Competing Interests: Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu